Blar i NTNU Open på forfatter "Lotfi, Kourosh"
-
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)
Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Höglund, Martin; Koskenvesa, Perttu; Lotfi, Kourosh; Majeed, Mohammed Waleed; Markevärn, Berit; Ohm, Lotta; Olsson-Strömberg, Ulla; Remes, Kari; Suominen, Merja; Simonsson, Bengt; Porkka, Kimmo; Mustjoki, Satu; Richter, Johan (Journal article, 2015)We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. ... -
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
Richter, Johan; Lübking, Anna; Söderlund, Stina; Lotfi, Kourosh; Markevärn, Berit; Själander, Anders; Stenke, Leif; Deneberg, Stefan; Ahlstrand, Erik; Myhr-Eriksson, Kristina; Panayiotidis, Panayiotis; Gedde-Dahl, Tobias; Žáčková, Daniela; Mayer, Jiří; Olsson-Strömberg, Ulla; Mahon, Francois-Xavier; Saussele, Susanne; Hjorth-Hansen, Henrik; Koskenvesa, Perttu (Peer reviewed; Journal article, 2021)